Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy

Shuanghu T. Yuan, Richard K.J. Brown, Lujun Zhao, Randall K. Ten Haken, Milton Gross, Kemp B. Cease, Matt Schipper, Paul Stanton, Jinming Yu, Feng Ming Kong

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To study whether esophageal FDG activity changes by time of mid-course of fractionated radiotherapy (RT), and whether these changes are associated with radiation esophagitis in patients with non-small cell lung cancer (NSCLC).Methods: Fifty patients with stage I-III NSCLC were enrolled prospectively and, all received ≥60 Gy RT. FDG-PET/CT scans were acquired prior to, and during-RT after delivery of 45 Gy. Normalized standardized uptake values (NSUV), defined by the esophageal maximum SUV relative to intravascular background level in the aortic arch, were sampled in the esophagus at the level of the primary tumor, sternal notch, aortic arch, carina, and gastro-esophageal junction. Symptomatic radiation esophagitis was defined as an event.Results: Compared to baseline, esophageal NSUV increased significantly during-RT at the level of the primary tumor (1.09 ± 0.05 vs.1.28 ± 0.06, p = 0.001), but did not change at other levels in the esophagus. 16 patients had radiation esophagitis events and these patients had significantly higher during-RT to baseline NSUV ratios than those without esophagitis (1.46 ± 0.12, 95% CI 1.20-1.71; vs. 1.11 ± 0.05, 95% CI 1.01-1.21, p = 0.002). Maximum esophageal dose (p = 0.029), concurrent chemotherapy (p = 0.022) and esophageal FDG PET NSUV ratio (during-RT to baseline, p = 0.007), were independent factors associated with esophagitis and area under curves (AUC) were 0.76, 0.70 and 0.78, respectively. Combining esophageal maximum dose and FDG PET NSUV Ratio at the tumor level increased AUC to 0.85 (p = 0.016).Conclusion: FDG uptake increased in esophagus during-RT and this increase may predict radiation esphagitis during later course of treatment.

Original languageEnglish (US)
Article number37
JournalRadiation Oncology
Volume9
Issue number1
DOIs
StatePublished - Jan 27 2014

Fingerprint

Esophagitis
Radiotherapy
Radiation
Esophagus
Thoracic Aorta
Non-Small Cell Lung Carcinoma
Area Under Curve
Neoplasms
Drug Therapy

Keywords

  • FDG PET
  • Non-small cell lung cancer
  • Radiation esophagitis
  • Standard uptake value (SUV)

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Yuan, S. T., Brown, R. K. J., Zhao, L., Ten Haken, R. K., Gross, M., Cease, K. B., ... Kong, F. M. (2014). Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. Radiation Oncology, 9(1), [37]. https://doi.org/10.1186/1748-717X-9-37

Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. / Yuan, Shuanghu T.; Brown, Richard K.J.; Zhao, Lujun; Ten Haken, Randall K.; Gross, Milton; Cease, Kemp B.; Schipper, Matt; Stanton, Paul; Yu, Jinming; Kong, Feng Ming.

In: Radiation Oncology, Vol. 9, No. 1, 37, 27.01.2014.

Research output: Contribution to journalArticle

Yuan, ST, Brown, RKJ, Zhao, L, Ten Haken, RK, Gross, M, Cease, KB, Schipper, M, Stanton, P, Yu, J & Kong, FM 2014, 'Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy', Radiation Oncology, vol. 9, no. 1, 37. https://doi.org/10.1186/1748-717X-9-37
Yuan, Shuanghu T. ; Brown, Richard K.J. ; Zhao, Lujun ; Ten Haken, Randall K. ; Gross, Milton ; Cease, Kemp B. ; Schipper, Matt ; Stanton, Paul ; Yu, Jinming ; Kong, Feng Ming. / Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy. In: Radiation Oncology. 2014 ; Vol. 9, No. 1.
@article{73a4963fad1149d6a83c4c2383b88b00,
title = "Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy",
abstract = "Purpose: To study whether esophageal FDG activity changes by time of mid-course of fractionated radiotherapy (RT), and whether these changes are associated with radiation esophagitis in patients with non-small cell lung cancer (NSCLC).Methods: Fifty patients with stage I-III NSCLC were enrolled prospectively and, all received ≥60 Gy RT. FDG-PET/CT scans were acquired prior to, and during-RT after delivery of 45 Gy. Normalized standardized uptake values (NSUV), defined by the esophageal maximum SUV relative to intravascular background level in the aortic arch, were sampled in the esophagus at the level of the primary tumor, sternal notch, aortic arch, carina, and gastro-esophageal junction. Symptomatic radiation esophagitis was defined as an event.Results: Compared to baseline, esophageal NSUV increased significantly during-RT at the level of the primary tumor (1.09 ± 0.05 vs.1.28 ± 0.06, p = 0.001), but did not change at other levels in the esophagus. 16 patients had radiation esophagitis events and these patients had significantly higher during-RT to baseline NSUV ratios than those without esophagitis (1.46 ± 0.12, 95{\%} CI 1.20-1.71; vs. 1.11 ± 0.05, 95{\%} CI 1.01-1.21, p = 0.002). Maximum esophageal dose (p = 0.029), concurrent chemotherapy (p = 0.022) and esophageal FDG PET NSUV ratio (during-RT to baseline, p = 0.007), were independent factors associated with esophagitis and area under curves (AUC) were 0.76, 0.70 and 0.78, respectively. Combining esophageal maximum dose and FDG PET NSUV Ratio at the tumor level increased AUC to 0.85 (p = 0.016).Conclusion: FDG uptake increased in esophagus during-RT and this increase may predict radiation esphagitis during later course of treatment.",
keywords = "FDG PET, Non-small cell lung cancer, Radiation esophagitis, Standard uptake value (SUV)",
author = "Yuan, {Shuanghu T.} and Brown, {Richard K.J.} and Lujun Zhao and {Ten Haken}, {Randall K.} and Milton Gross and Cease, {Kemp B.} and Matt Schipper and Paul Stanton and Jinming Yu and Kong, {Feng Ming}",
year = "2014",
month = "1",
day = "27",
doi = "10.1186/1748-717X-9-37",
language = "English (US)",
volume = "9",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy

AU - Yuan, Shuanghu T.

AU - Brown, Richard K.J.

AU - Zhao, Lujun

AU - Ten Haken, Randall K.

AU - Gross, Milton

AU - Cease, Kemp B.

AU - Schipper, Matt

AU - Stanton, Paul

AU - Yu, Jinming

AU - Kong, Feng Ming

PY - 2014/1/27

Y1 - 2014/1/27

N2 - Purpose: To study whether esophageal FDG activity changes by time of mid-course of fractionated radiotherapy (RT), and whether these changes are associated with radiation esophagitis in patients with non-small cell lung cancer (NSCLC).Methods: Fifty patients with stage I-III NSCLC were enrolled prospectively and, all received ≥60 Gy RT. FDG-PET/CT scans were acquired prior to, and during-RT after delivery of 45 Gy. Normalized standardized uptake values (NSUV), defined by the esophageal maximum SUV relative to intravascular background level in the aortic arch, were sampled in the esophagus at the level of the primary tumor, sternal notch, aortic arch, carina, and gastro-esophageal junction. Symptomatic radiation esophagitis was defined as an event.Results: Compared to baseline, esophageal NSUV increased significantly during-RT at the level of the primary tumor (1.09 ± 0.05 vs.1.28 ± 0.06, p = 0.001), but did not change at other levels in the esophagus. 16 patients had radiation esophagitis events and these patients had significantly higher during-RT to baseline NSUV ratios than those without esophagitis (1.46 ± 0.12, 95% CI 1.20-1.71; vs. 1.11 ± 0.05, 95% CI 1.01-1.21, p = 0.002). Maximum esophageal dose (p = 0.029), concurrent chemotherapy (p = 0.022) and esophageal FDG PET NSUV ratio (during-RT to baseline, p = 0.007), were independent factors associated with esophagitis and area under curves (AUC) were 0.76, 0.70 and 0.78, respectively. Combining esophageal maximum dose and FDG PET NSUV Ratio at the tumor level increased AUC to 0.85 (p = 0.016).Conclusion: FDG uptake increased in esophagus during-RT and this increase may predict radiation esphagitis during later course of treatment.

AB - Purpose: To study whether esophageal FDG activity changes by time of mid-course of fractionated radiotherapy (RT), and whether these changes are associated with radiation esophagitis in patients with non-small cell lung cancer (NSCLC).Methods: Fifty patients with stage I-III NSCLC were enrolled prospectively and, all received ≥60 Gy RT. FDG-PET/CT scans were acquired prior to, and during-RT after delivery of 45 Gy. Normalized standardized uptake values (NSUV), defined by the esophageal maximum SUV relative to intravascular background level in the aortic arch, were sampled in the esophagus at the level of the primary tumor, sternal notch, aortic arch, carina, and gastro-esophageal junction. Symptomatic radiation esophagitis was defined as an event.Results: Compared to baseline, esophageal NSUV increased significantly during-RT at the level of the primary tumor (1.09 ± 0.05 vs.1.28 ± 0.06, p = 0.001), but did not change at other levels in the esophagus. 16 patients had radiation esophagitis events and these patients had significantly higher during-RT to baseline NSUV ratios than those without esophagitis (1.46 ± 0.12, 95% CI 1.20-1.71; vs. 1.11 ± 0.05, 95% CI 1.01-1.21, p = 0.002). Maximum esophageal dose (p = 0.029), concurrent chemotherapy (p = 0.022) and esophageal FDG PET NSUV ratio (during-RT to baseline, p = 0.007), were independent factors associated with esophagitis and area under curves (AUC) were 0.76, 0.70 and 0.78, respectively. Combining esophageal maximum dose and FDG PET NSUV Ratio at the tumor level increased AUC to 0.85 (p = 0.016).Conclusion: FDG uptake increased in esophagus during-RT and this increase may predict radiation esphagitis during later course of treatment.

KW - FDG PET

KW - Non-small cell lung cancer

KW - Radiation esophagitis

KW - Standard uptake value (SUV)

UR - http://www.scopus.com/inward/record.url?scp=84899134675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899134675&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-9-37

DO - 10.1186/1748-717X-9-37

M3 - Article

VL - 9

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 37

ER -